ArticleOncology letters2019
RNA sequencing uncovers the key long non-coding RNAs and potential molecular mechanism contributing to XAV939-mediated inhibition of non-small cell lung cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 48 citations in OpenAlex.
- LINC00886 inhibits the proliferation, migration, and invasion of NSCLC cells by sponging miR-141-5p.Discover oncology · 2026Article
- The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer.European journal of medical research · 2025Review
- Ferroptosis and noncoding RNAs: exploring mechanisms in lung cancer treatment.Frontiers in cell and developmental biology · 2025Review
- The recent advancements of ferroptosis of gynecological cancer.Cancer cell international · 2024Review
- Article
- Coregulatory effects of multiple histone modifications in key ferroptosis-related genes for lung adenocarcinoma.Epigenomics · 2024Article
- Long non-coding RNAs in ferroptosis, pyroptosis and necroptosis: from functions to clinical implications in cancer therapy.Frontiers in oncology · 2024Review
- The Evaluation of Prognostic Value and Immune Characteristics of Ferroptosis-Related Genes in Lung Squamous Cell Carcinoma.Global medical genetics · 2023Article
- Ferroptosis in lung cancer: a novel pathway regulating cell death and a promising target for drug therapy.Cell death discovery · 2023Review
- Ferroptosis: a dual-edged sword in tumour growth.Frontiers in pharmacology · 2023Review
- A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.Bioscience reports · 2022Article
- Regulation of apoptosis, autophagy and ferroptosis by non-coding RNAs in metastatic non-small cell lung cancer (Review).Experimental and therapeutic medicine · 2022Review
- Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer.Frontiers in oncology · 2022Article
- Epigenetic Regulation of Ferroptosis-Associated Genes and Its Implication in Cancer Therapy.Frontiers in oncology · 2022Review
- Ferroptosis in Cancer Progression: Role of Noncoding RNAs.International journal of biological sciences · 2022Review
- The Prognostic Role of Cuproptosis in Head and Neck Squamous Cell Carcinoma Patients: A Comprehensive Analysis.Disease markers · 2022Article
- Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.American journal of translational research · 2022Article
- Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It.International journal of molecular sciences · 2021Review
- Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis.Cell death discovery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to reveal the key long non-coding RNAs (lncRNAs) and the potential molecular mechanisms of XAV939 treatment in non-small cell lung cancer (NSCLC). The NSCLC cell line, NCI-H1299, was cultured with 10 µM XAV939 for 12 h, and NCI-H1299 cells without XAV939 treatment were used as controls. Following RNA isolation from the two groups, RNA-sequencing was performed to detect transcript expression levels, and differentially-expressed lncRNAs (DE-lncRNAs) and DE-genes (DEGs) were identified between groups and analyzed for their functions and associated pathways. The potential associations between proteins encoded by DEGs were revealed via a protein-protein interaction (PPI) network. Subsequently, the microRNA (miRNA/miR)-mRNA, lncRNA-miRNA and lncRNA-mRNA interactions were explored, followed by competing endogenous RNA (ceRNA) network construction. A total of 396 DEGs and 224 DE-lncRNAs were identified between the XAV939 and control groups. These lncRNAs were mainly enriched in pathways such as 'ferroptosis' [DEG, solute carrier family 7 member 11 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.